SHAPING THE FUTURE WITH THE SWIRLING FLOW® STENT
n (Life Sciences & Allied Applications / Biology) the mimicking of life using imitation biological systems
04 October 2018: Veryan Medical is delighted to announce that the Company has received Premarket Approval (PMA)
for the BioMimics 3D Vascular Stent System from the U.S. Food & Drug Administration (FDA).
The device is approved for the treatment of symptomatic de novo or restenotic lesions in the
native superficial femoral artery and/or proximal popliteal artery.
VERYAN’S VASCULAR BIOMIMETIC STENT
IMPROVING PERFORMANCE BY IMITATING THE NATURAL 3D HELICAL SHAPE OF THE VASCULAR SYSTEM
Veryan has developed innovative technology to improve the performance of vascular stents by adopting the principle of biomimicry; developing structures that imitate those occurring naturally. Veryan’s vascular biomimetic stent technology involves adapting a straight stent design to a three-dimensional helical shape, which more closely mimics the natural geometry of the human vascular system. The BioMimics 3D stent belongs to a new generation of self-expanding stent design with advanced biomechanical and flow performance properties, creating the potential to transform the treatment of patients with symptomatic peripheral arterial disease of the lower limbs. This highly differentiated technology has been clinically proven in a multicentre, randomised clinical trial (the MIMICS study) and an FDA Investigational Device Exemption (IDE) multicentre clinical study conducted in US, Germany and Japan (MIMICS-2) and received CE Mark approval in November 2012 and US Premarket Approval (PMA) in October 2018 .